MNK has been the subject of a number of other reports. ValuEngine lowered shares of Mallinckrodt from a hold rating to a sell rating in a research report on Monday, April 2nd. Goldman Sachs reaffirmed a hold rating on shares of Mallinckrodt in a research report on Tuesday, December 26th. Canaccord Genuity set a $24.00 price objective on shares of Mallinckrodt and gave the company a hold rating in a research report on Sunday, January 7th. Oppenheimer reaffirmed a hold rating on shares of Mallinckrodt in a research report on Tuesday, February 27th. Finally, Mizuho reaffirmed a neutral rating and set a $21.00 price objective (down previously from $22.00) on shares of Mallinckrodt in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have assigned a buy rating to the company. Mallinckrodt currently has a consensus rating of Hold and a consensus target price of $33.89.
NYSE MNK opened at $13.79 on Thursday. The company has a quick ratio of 1.85, a current ratio of 2.18 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $1,199.41, a PE ratio of 1.84, a P/E/G ratio of 0.35 and a beta of 1.12. Mallinckrodt has a 52-week low of $13.32 and a 52-week high of $49.12.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.29. The business had revenue of $792.30 million during the quarter, compared to analyst estimates of $769.91 million. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The firm’s revenue was down 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.91 earnings per share. sell-side analysts predict that Mallinckrodt will post 6.17 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in MNK. State of Alaska Department of Revenue bought a new position in shares of Mallinckrodt in the fourth quarter valued at approximately $129,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Mallinckrodt in the fourth quarter valued at approximately $190,000. Shelton Capital Management bought a new position in shares of Mallinckrodt in the third quarter valued at approximately $205,000. Sciencast Management LP bought a new position in shares of Mallinckrodt in the fourth quarter valued at approximately $210,000. Finally, CIBC World Markets Inc. bought a new position in shares of Mallinckrodt in the fourth quarter valued at approximately $231,000. 97.38% of the stock is currently owned by institutional investors.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.